Wikisage, the free encyclopedia of the second generation, is digital heritage
Eslicarbazepine: Difference between revisions
Jump to navigation
Jump to search
(fix) |
m (→Mild inducers) |
||
(10 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
[[File:1Eslicarbazepine acetate structure.svg.png|thumb]] | [[File:1Eslicarbazepine acetate structure.svg.png|thumb]] | ||
S-licarbazepine is an [[antiepileptic drug|AED]]. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy<ref>Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases</ref><ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12894/epdf Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial]</ref> | S-licarbazepine is an [[antiepileptic drug|AED]]. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic [[epilepsy]] of infancy<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501557/pdf/main.pdf Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases]</ref><ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12894/epdf Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial]</ref> | ||
==Pharmacy and chemistry== | ==Pharmacy and chemistry== | ||
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | ||
Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to [[carbazepine]]; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
Line 16: | Line 16: | ||
*clobazam | *clobazam | ||
*eslicarbazepine | *eslicarbazepine | ||
*rufinamide | *[[rufinamide]] | ||
*felbamate | *felbamate | ||
*lamotrigine | *[[lamotrigine]] | ||
*oxcarbazepine | *[[oxcarbazepine]] | ||
*topiramate | *[[topiramate]] | ||
*vigabatrin | *vigabatrin | ||
*[[valproic acid|VPA]] | *[[valproic acid|VPA]] | ||
<ref>[http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90431353&pident_usuario=0&pcontactid=&pident_revista=486&ty=55&accion=L&origen=zonadelectura&web=www.elsevier.es&lan=en&fichero=486v08n02a90431353pdf001.pdf The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians ]</ref> | <ref>[http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90431353&pident_usuario=0&pcontactid=&pident_revista=486&ty=55&accion=L&origen=zonadelectura&web=www.elsevier.es&lan=en&fichero=486v08n02a90431353pdf001.pdf The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians ]</ref> | ||
===Cutaneous adverse effects=== | ===Cutaneous adverse effects=== | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231563/ Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231563/ Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine] | ||
Line 35: | Line 36: | ||
|} | |} | ||
== | {{Wikidata|Q410273}} | ||
==Bioequivalence== | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689905/pdf/40268_2013_Article_16.pdf Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689905/pdf/40268_2013_Article_16.pdf Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects] | ||
Latest revision as of 19:17, 13 October 2017
S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]
Pharmacy and chemistry
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]
Pharmacology
- Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
- Clinical utility of eslicarbazepine: current evidence
Mild inducers
After de Leon the following AED groups as mild inducers:
- clobazam
- eslicarbazepine
- rufinamide
- felbamate
- lamotrigine
- oxcarbazepine
- topiramate
- vigabatrin
- VPA
Cutaneous adverse effects
Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine
ATC code N03
Bioequivalence
References
- ↑ Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
- ↑ Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
- ↑ A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
- ↑ https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT
- ↑ The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AF04